In this study, cell-based assays showed that lorlatinib, in combination with EGFR blockade initiated during the initial phase, exerted significant inhibitory effects on ALK-rearranged NSCLC cells. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.